# Module 02 progression decision

- Phenotype and cohort score: `20.00 of 20.00`
- Gate result: `16 passed or passed with owned conditions; no failed gate`
- Progression: `continue with conditions`
- Module 03 permission: `permitted for curriculum construction`
- Decision owner: `APP-1 faculty owner with clinical phenotype and biostatistical methods review roles`
- Decision date: `2026-08-30 construction disposition`

| Condition ID | Condition | Owner | Due point | Evidence required | Escalation trigger | Status |
|---|---|---|---|---|---|---|
| C01 | Retain corrected Module 01 identity | data owner | every later release | version 0.2.0 and corrected manifest fingerprint | 485-person denominator reappears | open |
| C02 | Explain date-granular death rule | clinical phenotype reviewer | Module 03 | index and early death branches plus interpretation | death is treated as a precise timestamp | open |
| C03 | Preserve landmark exposure timing | methods reviewer | Module 03 | exposure assigned only at day 30 | exposure is treated as known at discharge | open |
| C04 | Explain competing-death boundary | survival methods reviewer | Module 03 | event and death ordering plus limitation | censoring is described as noninformative without support | open |
| C05 | Preserve extension provenance | synthetic-data reviewer | Modules 03 through 05 | seed probabilities field classes and zero direct effect | site is presented as source or real | open |
| C06 | Review missing patient and access evidence | patient or community reviewer | before Week 6 | measurement plan and response | encounter occurrence is treated as access or benefit | open |
| C07 | Complete named reproduction | independent reproducer | before alpha | clean build and validation record | output bytes or counts differ | open |
| C08 | Retain synthetic noncausal boundary | APP-1 faculty owner | every release | claim audit and acknowledgment | efficacy fairness ranking or implementation claim appears | open |

## Decision rationale

The complete source identity, corrected cohort flow, event audit, exposure timing, censoring fields, extension provenance, output fingerprints, and validation evidence are sufficient to begin Module 03 survival analysis. Progression remains conditional because clinical and methods interpretation, patient and access evidence, and named human reproduction remain pending.
